Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

TGF-β Score based on Silico Analysis can Robustly Predict Prognosis and Immunological Characteristics in Lower-grade Glioma: The Evidence from Multicenter Studies

Author(s): Weizhong Zhang, Zhiyuan Yan, Feng Zhao, Qinggui He and Hongbo Xu*

Volume 19, Issue 5, 2024

Published on: 19 September, 2023

Page: [610 - 621] Pages: 12

DOI: 10.2174/1574892819666230915143632

Price: $65

Abstract

Introduction: Nowadays, mounting evidence shows that variations in TGF-β signaling pathway-related components influence tumor development. Current research has patents describing the use of anti-TGF-β antibodies and checkpoint inhibitors for the treatment of proliferative diseases. Importantly, TGF-β signaling pathway is significant for lower-grade glioma (LGG) to evade host immunity. Loss of particular tumor antigens and shutdown of professional antigenpresenting cell activity may render the anti-tumor response ineffective in LGG patients. However, the prognostic significance of TGF-β related genes in LGG is still unknown.

Methods: We collected RNA-seq data from the GTEx database (normal cortical tissues), the Cancer Genome Atlas database (TCGA-LGG), and the Chinese Glioma Genome Atlas database (CGGA-693 and CGGA-325) for conducting our investigation.

Results: In addition, previous publications were explored for the 223 regulators of the TGF-β signaling pathway, and 30 regulators with abnormal expression in TCGA and GTEx database were identified. In order to identify hub prognostic regulators, least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression analysis were used to screen from differentially expressed genes (DEGs). On the basis of 11 genes from LASSO-Cox regression analysis (NEDD8, CHRD, TGFBR1, TP53, BMP2, LRRC32, THBS2, ID1, NOG, TNF, and SERPINE1), TGF-β score was calculated. Multiple statistical approaches verified the predictive value of the TGF-β score for the training cohort and two external validation cohorts. Considering the importance of the TGF-β signaling pathway in immune regulation, we evaluated the prediction of the TGF-β score for immunological characteristics and the possible application of the immunotherapeutic response using six algorithms (TIMER, CIBERSORT, QUANTISEQ, MCP-counter, XCELL and EPIC) and three immunotherapy cohorts (GSE78820, Imvigor-210 and PRJEB23709). Notably, we compared our risk signature with the signature in ten publications in the meta-cohort (TCGA-LGG, CGGA-693 and CGGA-325), and the TGF-β score had the best predictive efficiency (C-index =0.812).

Conclusion: In conclusion, our findings suggest that TGF-β signaling pathway-related signatures are prognostic biomarkers in LGG and provide a novel tool for tumor microenvironment (TME) assessment.

Keywords: LGG, tumor microenvironment, prognosis, TGF-β, immunological characteristics, GTEx database.

« Previous Next »
[1]
Duffau H, Taillandier L. New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach. Neuro-oncol 2014; 17(3): 332-42.
[http://dx.doi.org/10.1093/neuonc/nou153] [PMID: 25087230]
[2]
Wessels PH, Weber WEJ, Raven G, Ramaekers FCS, Hopman AHN, Twijnstra A. Supratentorial grade II astrocytoma: Biological features and clinical course. Lancet Neurol 2003; 2(7): 395-403.
[http://dx.doi.org/10.1016/S1474-4422(03)00434-4] [PMID: 12849117]
[3]
Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016; 131(6): 803-20.
[http://dx.doi.org/10.1007/s00401-016-1545-1] [PMID: 27157931]
[4]
Plant-Fox AS, O’Halloran K, Goldman S. Pediatric brain tumors: The era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae. Curr Probl Cancer 2021; 45(4): 100777.
[http://dx.doi.org/10.1016/j.currproblcancer.2021.100777] [PMID: 34303558]
[5]
Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol 2021; 151(1): 41-53.
[http://dx.doi.org/10.1007/s11060-020-03448-1] [PMID: 32253714]
[6]
Zhu Y, Song Z, Wang Z, Chen G. Protective prognostic biomarkers negatively correlated with macrophage M2 infiltration in low-grade glioma. J Oncol 2022; 2022: 3623591.
[http://dx.doi.org/10.1155/2022/3623591]
[7]
Kaminska B, Cyranowski S. Recent advances in understanding mechanisms of TGF beta signaling and its role in glioma pathogenesis. Adv Exp Med Biol 2020; 1202: 179-201.
[http://dx.doi.org/10.1007/978-3-030-30651-9_9] [PMID: 32034714]
[8]
Alcantara Llaguno S, Chen J, Kwon CH, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009; 15(1): 45-56.
[http://dx.doi.org/10.1016/j.ccr.2008.12.006] [PMID: 19111880]
[9]
Rich JN. The role of transforming growth factor-beta in primary brain tumors. Front Biosci 2003; 8: 245-60.
[http://dx.doi.org/10.2741/992]
[10]
Wesolowska A, Kwiatkowska A, Slomnicki L, et al. Microglia-derived TGF-β as an important regulator of glioblastoma invasion—an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor. Oncogene 2008; 27(7): 918-30.
[http://dx.doi.org/10.1038/sj.onc.1210683] [PMID: 17684491]
[11]
Rich JN, Zhang M, Datto MB, Bigner DD, Wang XF. Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem 1999; 274(49): 35053-8.
[http://dx.doi.org/10.1074/jbc.274.49.35053] [PMID: 10574984]
[12]
Dostalek M. Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases. US 20230056470, 2023.
[13]
Jin X, Zhang S, Wang N. High expression of TGF-β1 contributes to hepatocellular carcinoma prognosis via regulating tumor immunity. Front Oncol 2022; 12: 861601.
[http://dx.doi.org/10.3389/fonc.2022.861601]
[14]
Cao X, Zhang Q, Zhu Y, Huo X, Bao J, Su M. Derivation, comprehensive analysis, and assay validation of a pyroptosis-related lncRNA prognostic signature in patients with ovarian cancer. Front Oncol 2022; 12: 780950.
[http://dx.doi.org/10.3389/fonc.2022.780950]
[15]
Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study. Ann Oncol 2017; 28(12): 3044-50.
[http://dx.doi.org/10.1093/annonc/mdx518] [PMID: 28950298]
[16]
Zhou JG, Liang B, Liu JG, et al. Identification of 15 lncRNAs signature for predicting survival benefit of advanced melanoma patients treated with anti-PD-1 monotherapy. Cells 2021; 10(5): 977.
[http://dx.doi.org/10.3390/cells10050977]
[17]
Li B, Wang F, Wang N, Hou K, Du J. Identification of implications of angiogenesis and m6a modification on immunosuppression and therapeutic sensitivity in low-grade glioma by network computational analysis of subtypes and signatures. Front Immunol 2022; 13: 871564.
[http://dx.doi.org/10.3389/fimmu.2022.871564]
[18]
Wang L, Lv P, Lou Y. A Novel TAF-Related Signature Based on ECM Remodeling Genes Predicts Glioma Prognosis. Front Oncol 2022; 12: 862723.
[http://dx.doi.org/10.3389/fonc.2022.862723] [PMID: 35574375]
[19]
Zhou H, Meng M, Wang Z. The role of m5C-Related lncRNAs in predicting overall prognosis and regulating the lower grade glioma microenvironment. Front Oncol 2022; 12: 814742.
[http://dx.doi.org/10.3389/fonc.2022.814742]
[20]
Li J, Huang Q, Mo L. Comprehensive analysis of phagocytosis-related regulators to aid prognostic prediction and immunotherapy in patients with low-grade glioma. Dis Markers 2022; 2022: 1-22.
[http://dx.doi.org/10.1155/2022/4142684] [PMID: 35510040]
[21]
Zhu Y, Feng S, Song Z, et al. Identification of immunological characteristics and immune subtypes based on single-sample gene set enrichment analysis algorithm in lower-grade glioma. Front Genet 2022; 13: 894865.
[http://dx.doi.org/10.3389/fgene.2022.894865]
[22]
Ma J, Jin Y, Gong B, Li L, Zhao Q. Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance. Discov Oncol 2022; 13(1): 17.
[http://dx.doi.org/10.1007/s12672-022-00477-2]
[23]
Wang Y, Chen J, Chen C, et al. Growth differentiation factor-15 overexpression promotes cell proliferation and predicts poor prognosis in cerebral lower-grade gliomas correlated with hypoxia and glycolysis signature. Life Sci 2022; 302: 120645.
[http://dx.doi.org/10.1016/j.lfs.2022.120645] [PMID: 35588865]
[24]
Liu P, Wu R, Zhang J. Transcription factor signatures may predict the prognosis and status of the immune microenvironment of primary lower-grade gliomas. Int J Gen Med 2021; 14: 8173-83.
[http://dx.doi.org/10.2147/IJGM.S335399]
[25]
Wu D, Wang X, Xue Y, Sun C, Zhang M. Identification of a novel immune-related lncRNA signature to predict prognostic outcome and therapeutic efficacy of LGG. J Integr Neurosci 2022; 21(2): 055.
[http://dx.doi.org/10.31083/j.jin2102055] [PMID: 35364643]
[26]
a) Feng S, Yin H, Zhang K, et al. Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer. J Ovarian Res 2022; 15(1): 10.;
b) Thorsson V, Gibbs DL, Brown SD, et al. Immunity 2019; 51(2): 411-2. Erratum for: Immunity 2018; 48(4): 812-30.
[http://dx.doi.org/10.1016/j.immuni.2019.08.004] [PMID: 31433971] [http://dx.doi.org/10.1186/s13048-022-00944-y] [PMID: 35057848]
[27]
Zhou S, Zhao X, Yang Z, et al. Neddylation inhibition upregulates PD‐L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma. Int J Cancer 2019; 145(3): ijc.32379.
[http://dx.doi.org/10.1002/ijc.32379] [PMID: 31044422]
[28]
Hiraiwa M, Fukasawa K, Iezaki T, et al. SMURF2 phosphorylation at Thr249 modifies glioma stemness and tumorigenicity by regulating TGF-β receptor stability. Commun Biol 2022; 5(1): 22.
[http://dx.doi.org/10.1038/s42003-021-02950-0]
[29]
Sheng J, He X, Yu W, et al. p53-targeted lncRNA ST7-AS1 acts as a tumour suppressor by interacting with PTBP1 to suppress the Wnt/β-catenin signalling pathway in glioma. Cancer Lett 2021; 503: 54-68.
[http://dx.doi.org/10.1016/j.canlet.2020.12.039] [PMID: 33476649]
[30]
Fu C, Li D, Zhang X, Liu N, Chi G, Jin X. LncRNA PVT1 facilitates tumorigenesis and progression of glioma via regulation of MiR-128-3p/GREM1 Axis and BMP Signaling Pathway. Neurotherapeutics 2018; 15(4): 1139-57.
[http://dx.doi.org/10.1007/s13311-018-0649-9] [PMID: 30120709]
[31]
Chen X, Yang F, Zhang T. MiR-9 promotes tumorigenesis and angiogenesis and is activated by MYC and OCT4 in human glioma. J Exp Clin Cancer Res 2019; 38(1): 99.
[http://dx.doi.org/10.1186/s13046-019-1078-2]
[32]
Liu Q, Zhang C, Yuan J, et al. PTK7 regulates Id1 expression in CD44-high glioma cells. Neuro-oncol 2015; 17(4): 505-15.
[http://dx.doi.org/10.1093/neuonc/nou227] [PMID: 25204555]
[33]
Ratajczyk E, Ledzewicz U, Leszczynski M, Friedman A. The role of TNF-α inhibitor in glioma virotherapy: A mathematical model. Math Biosci Eng 2017; 14(1): 305-19.
[http://dx.doi.org/10.3934/mbe.2017020] [PMID: 27879135]
[34]
Huang X, Zhang F, He D. Immune-Related Gene SERPINE1 is a novel biomarker for diffuse lower-grade gliomas via large-scale analysis. Front Oncol 2021; 11: 646060.
[http://dx.doi.org/10.3389/fonc.2021.646060]

Rights & Permissions Print Cite
Article Metrics
14
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy